The Life Science Network

The Life Science Tennessee Network is beginning its fourth year and continues to make a positive impact on the entrepreneurial community in the life science industry.

In the spring of 2015, LST partnered with Launch Tennessee (LaunchTN) to launch the mentor network program. Since then, it has successfully connected seasoned mentors with exciting new companies, all while leveraging the wealth of knowledge available in our state’s accelerators. In October 2016, LST expanded its partnership with LaunchTN to bring a greater variety of services to companies and mentors in the program.

Currently, the program pulls from the expertise of more than 60 mentors. Modeled after San Diego’s CONNECT – Springboard program, mentors in the network guide participating companies through a process that helps fine-tune specific areas of a company’s investor pitch including overall presentation, finance, marketing, business strategy, intellectual property and other key aspects.

To graduate, companies must give a final presentation to an audience that includes investors. The goal of the program is to leverage the expertise of mentors in the network to help these companies produce the best, most polished pitch possible. As we continue to grow, we also plan to bolster the life science industry in Tennessee by creating strong community ties between mentors in the network and between mentors and entrepreneurs.

For more information on the Life Science Network, click HERE.

Jim Monsor

Jim leads the Life Science TN Mentor program. He has more than 33 years of device, diagnostic, drug, biologics and combination product experience. He is currently CEO of Relay Life Science. Most recently he served as COO for BioMimetic Therapeutics for 12 years, leading growth from four to 100 employees through multiple regulatory approvals. He has broad experience in operations, supply chain management, early stage R&D, product development, tech transfer, quality system, product approvals, regulatory, IT and facilities management for bulk drug and finished products. His experience spans early stage research through all phases of development product launch, and routine commercial operations.